Citius Oncology
Citius Oncology (NASDAQ: CTOR) is a biopharmaceutical company that develops and commercializes LYMPHIR (denileukin diftitox-cxdl), an FDA-approved recombinant IL-2-diphtheria toxin fusion protein for adults with relapsed or refractory cutaneous T-cell lymphoma, while exploring combination therapy indications in solid tumors and hematologic malignancies.
- Company typePublic
- Founded2024
- HeadquartersCranford, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Citius Oncology does
Citius Oncology, Inc. (NASDAQ: CTOR) is a biopharmaceutical company focused on developing and commercializing innovative targeted oncology therapies, with a single approved and commercially launched product, LYMPHIR (denileukin diftitox-cxdl). The company became publicly traded on August 12, 2024 following its merger with TenX Keane Acquisition, and operates as a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), with the parent holding approximately 71% ownership and shared executive leadership including Chairman and CEO Leonard Mazur.
LYMPHIR is a recombinant fusion protein that combines an IL-2 receptor binding domain with diphtheria toxin fragments. The molecule is engineered to bind to IL-2 receptors on cell surfaces and deliver the diphtheria toxin payload into tumor cells, inhibiting protein synthesis and causing cell death, while also transiently depleting immunosuppressive regulatory T cells (Tregs) to enhance anti-tumor immune response. The FDA approved LYMPHIR on August 7, 2024 for adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy, and the company launched the product commercially in the United States in December 2025. Beyond the approved CTCL indication, Citius Oncology is pursuing LYMPHIR as a combination platform through investigator-initiated trials evaluating the asset in diffuse large B-cell lymphoma (DLBCL) prior to CAR-T therapy (86% ORR in Phase 1) and in combination with pembrolizumab for recurrent or refractory gynecologic malignancies (24% ORR, 48% clinical benefit rate).
Citius Oncology generates revenue from direct sales of LYMPHIR to U.S. pharmaceutical distributors (McKesson plus two others) and through regional distribution partners internationally, with the company utilizing EVERSANA for integrated commercialization services and Verix for AI-powered physician targeting. Net product revenue totaled $5.6 million for the first half of fiscal 2026 with approximately 80% gross margins, while international access is currently limited to Named Patient Programs across 19 markets through exclusive distribution agreements with Uniphar (Europe) and Er-Kim (Turkey, GCC countries). The company is headquartered in Cranford, New Jersey, operates with a lean 1-10 employee base, and is led by an executive team with deep specialty pharmaceutical commercialization experience including prior roles at Celgene, Roche Laboratories, and multiple specialty pharma ventures.
Citius Oncology firmographics
Firmographics- Name
- Citius Oncology
- Legal name
- Citius Oncology, Inc.
- Website
- https://citiusonc.com
- Company type
- Public
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Citius Oncology (NASDAQ: CTOR) is a biopharmaceutical company that develops and commercializes LYMPHIR (denileukin diftitox-cxdl), an FDA-approved recombinant IL-2-diphtheria toxin fusion protein for adults with relapsed or refractory cutaneous T-cell lymphoma, while exploring combination therapy indications in solid tumors and hematologic malignancies.
- Ownership category
- akta.pro rank
Citius Oncology industry classification
Industry- Product category
- Biopharmaceutical Oncology Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)
Keywords
Where Citius Oncology is headquartered
LocationHeadquarters
- HQ city
- Cranford
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Citius Oncology business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Marketing or Sales, Technology or R&D, Personnel, Operations, Others
Revenue model
- LYMPHIR Product Sales: Citius Oncology generates revenue from direct sales of LYMPHIR to U.S. distributors (McKesson and others) and through regional distribution partners internationally. The product was commercially launched in December 2025 with $3.9 million Q1 2026 revenue and $1.7 million Q2 2026 revenue, achieving approximately 80% gross margins.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Other | LYMPHIR for relapsed/refractory CTCL |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels5 records
Citius Oncology product offering
Product offeringCore offering
Citius Oncology develops and commercializes LYMPHIR (denileukin diftitox-cxdl), an FDA-approved recombinant IL-2-diphtheria toxin fusion protein for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. The company is also advancing LYMPHIR as a combination therapy with checkpoint inhibitors (pembrolizumab) and as a bridging agent prior to CAR-T therapy through investigator-initiated Phase 1 trials.
Product overview
Citius Oncology is a biopharmaceutical company with a single commercial product, LYMPHIR (denileukin diftitox-cxdl), an FDA-approved targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma. The company is exploring LYMPHIR's potential as a platform asset through investigator-initiated combination therapy trials with pembrolizumab in gynecologic cancers and as a pre-treatment for CAR-T therapy in diffuse large B-cell lymphoma. LYMPHIR is the company's only marketed product and represents its complete commercial portfolio.
Differentiator
Problem solved
Functional benefit
Brands
- LYMPHIR (denileukin diftitox-cxdl): FDA-approved targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL)
Products and services
- LYMPHIR (denileukin diftitox-cxdl) Targeted immune therapy combining an IL-2 receptor binding domain with diphtheria toxin fragments, FDA-approved for treating adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma after at least one prior systemic therapy. It binds IL-2 receptors on tumor cells, delivers diphtheria toxin that inhibits protein synthesis causing cell death, and depletes immunosuppressive regulatory T lymphocytes. Sold to physicians, hospitals, and specialty pharmacies through pharmaceutical distributors and regional partners.
Quantifiable outcome
- 86% overall response rate in high-risk relapsed/refractory DLBCL patients when LYMPHIR was administered prior to CAR-T therapy (57% complete responses, 29% partial responses)
- +4 more outcomes
Companies that use Citius Oncology
Customer profileSegments1 record
Ideal customer profiles1 record
Citius Oncology technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
Feature2 records
Citius Oncology partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and minor.
- UnipharcoreExclusive distribution agreement with Uniphar to supply LYMPHIR across designated territories in Western and Eastern Europe through country-specific managed access programs. Uniphar handles market access and distribution activities while Citius Oncology supplies finished product.
- Er-KimcoreExclusive agreement with Er-Kim to expand distribution of LYMPHIR to Turkey and Gulf Cooperation Council countries, extending international reach to 19 markets outside the U.S.
- McKesson CorporationcoreU.S. distribution agreement with McKesson to support the commercial launch of LYMPHIR. This alliance completed Citius Oncology's distribution network with the three largest U.S. pharmaceutical distributors to ensure broad access to the therapy.
- EVERSANAcoreExclusive agreement with EVERSANA to support U.S. commercialization of LYMPHIR with integrated services for market entry and launch readiness.
- UPMC Magee-Womens Hospital (University of Pittsburgh Medical Center)coreInvestigator-initiated Phase 1 trial evaluating LYMPHIR in combination with pembrolizumab in patients with recurrent or metastatic solid tumors, primarily gynecologic malignancies. Study demonstrated 24% objective response rate and 48% clinical benefit rate. Results presented at ASCO 2026.
- University of Minnesota, Masonic Cancer CentercoreInvestigator-initiated Phase 1 trial evaluating LYMPHIR administered prior to CAR-T therapy in patients with high-risk relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Trial demonstrated 86% overall response rate with 57% complete responses. Citius Oncology provided study drug and financial support.
- City of HopeminorInvestigator-initiated trial site for LYMPHIR prior to CAR-T therapy study in DLBCL patients, conducted at University of Minnesota and City of Hope.
Scale indicators9 records
Recent moves9 records
Expansion highlights6 records
Citius Oncology competitors and assessment
Company assessmentDirect peers
- Soligenix: Soligenix is a late-stage biopharmaceutical company developing SGX301 (synthetic hypericin) for early-stage cutaneous T-cell lymphoma. Direct competitor in the CTCL treatment space with overlapping prescriber base of dermatologists and oncologists treating rare lymphoma indications.
- Verastem Oncology: Verastem markets COPIKTRA (duvelisib), an FDA-approved treatment for relapsed/refractory CLL/SLL and FL, and has historically pursued CTCL with the same hematology/oncology specialty channel. Competes for the same specialty prescriber relationships and oncology distribution infrastructure.
- Kyowa Kirin: Kyowa Kirin markets POTELIGEO (mogamulizumab), an FDA-approved CCR4-directed antibody for relapsed/refractory mycosis fungoides and Sézary syndrome (forms of CTCL). The most established systemic therapy competitor in the exact CTCL patient population Citius targets.
- ADC Therapeutics: ADC Therapeutics develops antibody-drug conjugates for hematologic malignancies, including ZYNLONTA for DLBCL. Comparable as a small-cap commercial-stage oncology biotech with biologic modality, similar institutional ownership profile, and overlapping lymphoma development strategy with LYMPHIR's DLBCL pre-CAR-T positioning.
- Innate Pharma: Innate Pharma is a clinical-stage immuno-oncology company developing antibody-based therapeutics targeting immune regulatory pathways, including NK cell engagers and checkpoint modulators. Direct peer in immuno-oncology with similar focus on modulating the tumor microenvironment — directly comparable to LYMPHIR's Treg depletion mechanism.
- Karyopharm Therapeutics: Karyopharm commercializes XPOVIO (selinexor) for multiple myeloma and DLBCL. Small-cap specialty oncology biotech with biologic-like commercial model, similar reliance on specialty distribution, and active lymphoma development pipeline that overlaps with LYMPHIR's DLBCL pre-CAR-T strategy.
- Acrotech Biopharma: Acrotech Biopharma is a specialty oncology company developing and commercializing novel therapies for lymphomas and difficult-to-treat cancers, with FDA-approved products including FOLOTYN. Comparable as a small/mid-cap specialty pharma focused on hematologic malignancies with similar distribution and physician engagement model.
- Eagle Pharmaceuticals: Eagle Pharmaceuticals is a specialty pharmaceutical company focused on hospital and oncology products, including bendamustine for lymphoma treatment. Comparable business model as a small-cap specialty pharma commercializing oncology biologics/specialty drugs through specialty distribution networks.
- Helsinn Group: Helsinn is a privately-held specialty pharma focused on cancer supportive care and oncology therapeutics with global commercial infrastructure. Comparable as a mid-sized specialty oncology company with established international distribution partnerships and biologic/specialty product portfolio.
Broad incumbents
- Takeda Pharmaceutical (Adcetris franchise): Takeda markets Adcetris (brentuximab vedotin), an antibody-drug conjugate approved for CTCL and other T-cell lymphomas. Broad incumbent with established CTCL commercial footprint and physician relationships that overlap with LYMPHIR's target prescribers.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
Citius Oncology social profiles
Digital presenceCitius Oncology compliance and trust
Trust signalCompliance1 record
Citius Oncology financial estimates
Financial estimateRevenue estimate
Valuation estimate
Citius Oncology leadership team
Management profileNumber of profiles
Profiles4 records
Citius Oncology funding detail
Funding detailFunding overview
Funding rounds5 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Citius Oncology M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Citius Oncology
What does Citius Oncology do?
Citius Oncology develops and commercializes LYMPHIR (denileukin diftitox-cxdl), an FDA-approved recombinant IL-2-diphtheria toxin fusion protein for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. The company is also advancing LYMPHIR as a combination therapy with checkpoint inhibitors (pembrolizumab) and as a bridging agent prior to CAR-T therapy through investigator-initiated Phase 1 trials.
Is Citius Oncology a public or private company?
Citius Oncology is a public company. It is classified as public and is currently operating.
When was Citius Oncology founded?
Citius Oncology was founded in 2024. It employs 11 to 50 people.
Where is Citius Oncology based?
Citius Oncology is headquartered in Cranford, United States, in the North America region.
How does Citius Oncology make money?
One revenue line is on record: LYMPHIR Product Sales.
Who are Citius Oncology's main competitors?
Direct peers on record are Soligenix, Verastem Oncology, Kyowa Kirin, ADC Therapeutics, Innate Pharma, Karyopharm Therapeutics, Acrotech Biopharma, Eagle Pharmaceuticals and Helsinn Group. Takeda Pharmaceutical (Adcetris franchise) is listed as a broad incumbent.
Does Citius Oncology have an API?
No public API is recorded for Citius Oncology.
What industry is Citius Oncology in?
Citius Oncology's product category is Biopharmaceutical Oncology Therapeutics. Its primary akta.pro industry code is HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.